Etiopathogenesis of primary sclerosing cholangitis

被引:104
作者
O'Mahony, Christine A.
Vierling, John M.
机构
[1] Baylor Coll Med, Dept Surg, Houston, TX 77030 USA
[2] Baylor Coll Med, Dept Med, Houston, TX 77030 USA
关键词
primary sclerosing cholangitis; biliary; biliary cirrhosis; etiology; pathogenesis; immunology; inflammatory bowel disease; colitis; ulcerative colitis; Crohn colitis;
D O I
10.1055/s-2006-933559
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The etiopathogenesis of primary sclerosing cholangitis (PSC) remains undefined. Immunopathogenetic mechanisms appear to be involved, based on human leukocyte antigen complex susceptibility associations, existence of multiple autoantibodies, and presence of inflammatory bowel disease in > 75% of patients. PSC may represent an autoimmune disease with atypical features or an immune-mediated inflammatory disease, similar to inflammatory bowel disease itself Immunogenetic susceptibility is closely linked to ligands for innate immune cells and capacity for sustained production of proinflammatory cytokines. Immunopathogenesis involves a multistep process initiated by the activation of cholangiocyte by bacterial pathogen-associated molecular patterns (stimuli of innate immunity) and proinflammatory cytokines in conjunction with aberrant expression of gut-specific chemokines and endothelial cell adhesion molecules in the liver. After recruitment of gut-primed memory T cells into the portal tracts and peribillary space, additional mechanisms produce focal, fibrous, obliterative lesions. Progressive periductal fibrosis, chronic inflammation, and ischemic atrophy of biliary epithelia result in ductopenia, cholestasis, and obstructive strictures, culminating in secondary biliary cirrhosis.
引用
收藏
页码:3 / 21
页数:19
相关论文
共 139 条
[1]   Impact of the-308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: relevance to disease [J].
Abraham, LJ ;
Kroeger, KM .
JOURNAL OF LEUKOCYTE BIOLOGY, 1999, 66 (04) :562-566
[2]  
Adams DH, 2002, FRONT BIOSCI-LANDMRK, V7, pE276
[3]  
ADAMS DH, 2005, NIDDK RES WORKSH PRI
[4]   The pathobiology of biliary epithelia [J].
Alpini, G ;
McGill, JM ;
LaRusso, NF .
HEPATOLOGY, 2002, 35 (05) :1256-1268
[5]   Serum autoantibodies in patients with primary sclerosing cholangitis [J].
Angulo, P ;
Peter, JB ;
Gershwin, ME ;
DeSotel, CK ;
Shoenfeld, Y ;
Ahmed, AEE ;
Lindor, KD .
JOURNAL OF HEPATOLOGY, 2000, 32 (02) :182-187
[6]   Detection of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis: A comparison of the alkaline phosphatase and immunofluorescent techniques [J].
Bansi, DS ;
Bauducci, M ;
Bergqvist, A ;
Boberg, K ;
Broome, U ;
Chapman, R ;
Fleming, K ;
Jorgensen, R ;
Lindor, K ;
Rosina, F ;
Schrumpf, E .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1997, 9 (06) :575-580
[7]  
Batis KP, 1998, MAYO CLIN PROC, V73, P380
[8]   Adaptative bile duct proliferative response in experimental bile duct ischemia [J].
Beaussier, M ;
Wendum, D ;
Fouassier, L ;
Rey, C ;
Barbu, V ;
Lasnier, E ;
Lienhart, A ;
Scoazec, JY ;
Rosmorduc, O ;
Housset, C .
JOURNAL OF HEPATOLOGY, 2005, 42 (02) :257-265
[9]  
Benninger J, 2005, WORLD J GASTROENTERO, V11, P4199
[10]   Intestinal permeability and bacterial growth of the small bowel in patients with primary sclerosing cholangitis [J].
Björnsson, E ;
Cederborg, A ;
Åkvist, A ;
Simren, M ;
Stotzer, PO ;
Bjarnason, I .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2005, 40 (09) :1090-1094